TLDR
- Can-Fite BioPharma’s Phase 2a trial of namodenoson in advanced pancreatic cancer met its primary safety endpoint with no new safety signals.
- The study enrolled 20 heavily pretreated patients with advanced pancreatic ductal adenocarcinoma (PDAC).
- About one-third of patients were still alive at the data cut-off, with survival follow-up ongoing.
- Namodenoson holds Orphan Drug Designation from the FDA for pancreatic cancer treatment.
- Results are expected to be presented at upcoming scientific conferences, with more mature survival data to follow.
Can-Fite BioPharma reported positive Phase 2a safety results for namodenoson in advanced pancreatic cancer on March 4, 2026. The drug was well tolerated in 20 pretreated patients with no new safety signals. Around one-third of patients remained alive at the data cut-off, with survival follow-up still ongoing.
Can-Fite’s Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer Studyhttps://t.co/DEDKvzjg6h$CANF
— Can-Fite BioPharma (@CanFitePharma) March 4, 2026
Namodenoson is a selective A3 adenosine receptor agonist. It works by targeting a receptor that is more expressed in cancerous and inflammatory cells than in normal cells. Can-Fite has been developing it across multiple cancer types, including liver cancer.
The pancreatic cancer study was open-label and enrolled patients who had already failed prior systemic therapies. This is a particularly difficult patient group. Pancreatic cancer has one of the lowest survival rates of any cancer, and patients who have exhausted treatment options have very few alternatives.
The 20 patients in the trial had diverse health profiles and many had metastatic disease. Some had received two or more prior lines of therapy, making them a high-risk cohort.
The primary endpoint of the trial was safety. Namodenoson cleared that bar. Secondary endpoints included overall survival and progression-free survival. Those results are still maturing.
Orphan Drug Status
The FDA has granted namodenoson Orphan Drug Designation for pancreatic cancer. This status is given to drugs targeting rare diseases and comes with benefits including market exclusivity and development incentives.
Can-Fite also has namodenoson in trials for advanced liver cancer. The drug is one of the company’s lead pipeline assets alongside piclidenoson, which targets psoriasis.
The company plans to present more complete survival data at future scientific conferences. No specific event or date has been announced yet.
Financial Picture
Can-Fite is a clinical-stage company. It has not generated meaningful revenue from product sales and is operating at a loss. Revenue has declined at a rate of -41.5% over the past three years.
The operating margin sits at -1,595%, and the company carries an Altman Z-Score of -26.39, a measure that points to financial distress. Institutional ownership is low at 3.49%.
The current market cap is approximately $6.24 million, making CANF a micro-cap stock. The stock saw a one-day move of +107.80% following the news release on March 4.
The most recent analyst rating on CANF is a Hold, with a price target of $0.20. That target stands in contrast to the stock’s sharp move higher on the trial news.
Considering a new stock? You may want to see what’s on our watchlist first.
Our team at Knockout Stocks follows top-performing analysts and market-moving trends to spot potential winners early. We’ve identified five stocks gaining quiet attention that could be worth watching now. Create your free account to unlock the full report and get ongoing stock insights.Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
